Gliptinaid 20 Tablet contains Teneligliptin 20 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. These hormones stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppress glucagon release from alpha cells, resulting in improved glycemic control. Gliptinaid 20 is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled with monotherapy or combination therapy. The medication is well tolerated with a low risk of hypoglycemia when used as monotherapy or in combination with agents not associated with hypoglycemia. It is administered orally once daily, with or without food. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy. Gliptinaid 20 should be used under medical supervision, and patients should be informed about potential side effects such as nasopharyngitis, headache, and gastrointestinal disturbances.